Data from the Majestec‑3 trial presented at ASH showed the combination of Janssen’s teclistamab and daratumumab produced an 83.4% three‑year progression‑free survival rate versus 29.7% for standard care, investigators reported. Presenters described the steep PFS separation and plateauing curves as evidence of a potentially transformational effect in relapsed multiple myeloma. Maria‑Victoria Mateos, reporting at the American Society of Hematology, called the magnitude of effect “the greatest PFS treatment effect we’ve seen to date.” Teclistamab (Tecvayli) redirects T cells against BCMA while daratumumab (Darzalex) modulates the tumor microenvironment; the companies provided pooled follow‑up and survival readouts. The readout adds momentum to bispecific antibody strategies and may influence earlier use of teclistamab‑based regimens, with implications for sequencing against autologous CAR‑T therapies and other high‑efficacy options.